The first clinical results are impressive

Press release from NOLabs AB 2009-01-20

Topical administration of NO has the potential of becoming a new treatment concept for neuropathic pain in diabetics.

NOLabs AB, the Swedish Medtech Company developing innovative nitric oxide-containing medical devices based on the NitroSense® Technology, today reported that it has achieved another important milestone in the development of a new line of products where a topical administration of NO has the potential becoming a new treatment concept for neuropathic pain in diabetics.

Significant unmet clinical need for diabetic patients and more than 200 million people suffer from diabetes globally. Peripheral diabetic neuropathy is one of the most common late complications (about 40%). It is frequently associated with pain, involving predominantly the lower limbs.

• The first clinical results are impressive. Preliminary result is available from ten patients in an on-going study with diabetic, type-2, patients suffering from painful neuropathy.
• There was a 50-60% pain relief comparing pain scores before and after three weeks treatment.

Contact: CEO Göran Beijer

E-mail: goran.beijer@nolabs.com
Phone: +46 70 663 60 09